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Abstract
Objective The aim of this retrospective study was to compare surgical and survival outcome in only patients with early-stage 
UCSs managed by laparotomic surgery (LPT) versus minimally invasive surgery (MIS).
Methods Data were retrospectively collected in four Italian different institutions. Inclusion criteria were UCS diagnosis 
confirmed by the definitive histological examination, and stage I or II according to the FIGO staging system.
Results Between August 2000 and March 2019, the data relative to 170 patients bearing UCSs were collected: of these, 95 
were defined as early-stage disease (stage I–II) based on the histological report at the primary surgery, and thus were included 
in this study. Forty-four patients were managed by LPT, and 51 patients were managed by MIS. The operative time was 
lower in the MIS group versus the LPT group (p value 0.021); the median estimated blood loss was less in the MIS group 
compared to the median of LPT group (p value < 0.0001). The length of hospital stay days was shorter in the MIS patients 
(p value < 0.0001). Overall, there were eight (8.4%) post-operative complications; of these, seven were recorded in the LPT 
group versus one in the MIS group (p value 0.023). There was no difference in the disease-free survival (DFS) and overall 
survival (OS) between the two groups.
Conclusion There was no difference of oncologic outcome between the two approaches, in face of a more favourable peri-
operative and post-operative profile in the MIS group.
Keywords Uterine carcinosarcoma · Minimally invasive surgery · Open surgery
Introduction
Uterine carcinosarcomas (UCSs) are rare and aggressive 
malignancies characterized by the concomitant presence of 
carcinomatous and sarcomatous components (Akahira et al. 
2006; Cantrell et al. 2015). UCSs account for less than 5% 
of all uterine tumors, however, a recent study conducted in 
the USA has reported that the rate of this disease has signifi-
cantly increased over time, possibly due to the increase of 
number of older patients, obesity, increased use of tamox-
ifen, etc. (Pothuri et al. 2006; Onstad et al. 2016; Matsuo 
et al. 2018). Even though UCSs are considered as meta-
plastic endometrial carcinomas (EC), their aggressiveness 
is much higher compared to the classical EC; indeed, the 
proportion of stage I–II is lower in UCSs compared to EC, 
and, even in early stage, UCSs patients experience worse 
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prognosis with a 5-years survival of 60% (Gonzalez Bosquet 
et al. 2010).
In addition, high grade, older age, and lymphovascular 
space invasion are more frequently documented in UCSs 
than in other EC types (Cantrell et al. 2015; Abdulfatah et al. 
2019). In this context, it has also to be acknowledged that 
UCSs display a mutational profile endowed with high copy 
number, and unfavourable clinical outcome (The Cancer 
Genome Atlas Research Network and Levine 2013; Leskela 
et al. 2019; Carlson and McCluggage 2019).
In early-stage disease, surgery represents the milestone 
of treatment, and includes total hysterectomy, bilateral 
salpingo-oophorectomy, pelvic and aortic lymphadenec-
tomy, and peritoneal biopsies (Baekelandt and Castiglione 
2009; Denschlag and Ulrich 2018) www.nccng uidel ines.gov 
(2020); even though omentectomy or omental al sampling 
are not formally recommended, these procedures often car-
ried out probably because microscopic involvement has been 
shown to account for 35% of omental disease, and thus could 
be missed (Ross et al. 2018).
The most frequent surgical approach adopted in early 
UCSs is laparotomy, and few retrospective data are available 
relative to the minimally invasive surgery in UCSs (Wallwie-
ner et al. 2016; Tan et al. 2017; Dellinger et al. 2017); within 
the GOG LAP2 trial (Walker et al. 2009), which has investi-
gated the clinical outcome of early-stage EC patients triaged 
to laparoscopic versus laparotomic surgery, the sub-group 
analysis of “high risk” histotypes (i.e. clear cells, serous, 
and UCSs) reported similar rates of recurrence and survival 
between the two approaches (Fader et al. 2016).
The aim of this retrospective study was to compare surgi-
cal and survival outcome in only patients with early-stage 
UCSs managed by laparotomic surgery (LPT) versus mini-
mally invasive surgery (MIS).
Patients and methods
Data were retrospectively collected in four different insti-
tutions: “Fondazione Policlinico Universitario A. Gemelli” 
Rome, “Regina Elena National Cancer Institute” Rome, 
“Gemelli Molise spa, Università Cattolica del Sacro Cuore” 
Campobasso, and the “Miulli hospital”, Acquaviva delle 
Fonti in Bari. This study was approved by the internal review 
board at each participating institution. All patients had 
already provided a written informed consent for their data 
to be collected and analysed for scientific purpose, according 
to our institutional policy.
Inclusion criteria were UCS diagnosis confirmed by the 
definitive histological examination, and stage I or II accord-
ing to the FIGO staging system (Creasman 2009).
Patients with anesthesiological contraindications for the 
MIS approach (i.e. patients who could not sustain a steep 
Trendeleburg position) were triaged to laparotomic surgery. 
Previous abdominal surgery was not considered an exclu-
sion criterion.
All patients were evaluated before surgery by means of 
medical history, physical examination, vaginal–pelvic exam-
ination, chest X-ray or chest CT, pelvic ultrasound scans 
and complete abdomen and pelvis CT scan or MRI; PET/
CT scans if any suspicious images in previous examinations.
Details relative to the type of hysterectomy according to 
the Querleu-Morrow classification (Querleu and Morrow 
2008), and lymph node assessment (i.e. systematic lymphad-
enectomy or lymph node sampling or sentinel lymph node 
technique (SLN) were collected in both groups.
Intraoperative and postoperative complications were 
defined according to Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.3 (U.S. Department of 
Health and Human Services 2009).
Adjuvant therapy was tailored to the pathologic find-
ings at the primary surgery after multidisciplinary tumor 
board (gynecologic oncology, pathology, radiation oncol-
ogy, medical oncology) discussion. Adjuvant chemotherapy 
including always platinum/paclitaxel or just platinum in unfit 
patients. The vast majority of adjuvant radiotherapy was rep-
resented by external beam pelvic irradiation (45–50 Gy) plus 
brachytherapy in case of cervical involvement. Treatment 
was based on the National Comprehensive Cancer Network 
(NCCN) guidelines (www.nccn.org.professionals.physi-
cian_gls) as well as ESGO, and ESTRO guidelines (Baeke-
landt and Castiglione 2009; Creasman 2009; Plataniotis and 
Castiglione 2010; Colombo et al. 2016).
The data relative to the time interval from surgery to 
the start of adjuvant therapy were calculated, if available. 
Follow-up data were recorded through phone calls, if not 
available from medical records.
Follow-up schedule include clinical and gynecological 
examination, CA125 level and ultrasound pelvic scan every 
3 months in the first 2 years and every 6 months thereaf-
ter; abdomen and thorax CT scan after the end of adjuvant 
treatment and every 6 months in the first 2 years and every 
12 months thereafter. In case of undefined lesions to ultra-
sound or CT scan, it is scheduled a PET/CT.
Statistical analysis
Descriptive analysis of data was carried out by Fisher’s exact 
test for proportion for categorical data or Wilcoxon rank sum 
non-parametric test for continuous variables. Disease-free 
survival (DFS) would be calculated from the date of surgery 
up to disease progression or the date last seen; overall sur-
vival (OS) would be calculated from the date of surgery up 
to death of disease or the date last seen. Survival estimates 
would be analysed by the Kaplan–Meier method, and the 
log rank test would be used to assess statistical significance. 
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Multivariate analysis of prognostic factors would be carried 
out by the Cox regression model. The SPSS software (SPSS 
version 21.0, SPSS Inc., Chicago, Illinois, USA) was used 
for all statistical evaluations.
Results
Between August 2000 and March 2019, the data relative 
to 170 patients bearing UCSs were collected; of these, 95 
were defined as early-stage disease (stage I–II) based on the 
histological report at the primary surgery, and thus were 
included in this study. Forty-four patients were managed by 
LPT, and 51 patients were managed by MIS. About 75% of 
patients have been enrolled in the last 10 years.
Table 1 shows the patients features in the whole series, 
as well as in the LPT and MIS groups: in the whole series, 
the median age was 67 years (range 39–88), the median 
BMI was 28 kg/m2 (range 19–47), and the vast majority of 
patients (N = 73, 76.8%) referred comorbidities; age, BMI, 
and proportion of patients with comorbidities did not differ 
between the LPT group and the MIS one.
As far as surgical procedures are concerned, the vast 
majority of patients in the whole series (N = 81, 85.3%) 
underwent type A hysterectomy; type B1 hysterectomy was 
less frequently carried out in the MIS group than in the LPT 
group (p value = 0.042). In the whole series, assessment of 
pelvic lymph node status was carried out by lymphadenec-
tomy (N = 47, 49.5%), or sampling (N = 9, 9.5%), while very 
old and/or unfitted patients, and patients intraoperatively 
judged to harbour excessive tissue fragility (N = 39) were not 
triaged to pelvic lymph node assessment; there was no differ-
ence in the distribution of lymph node procedures between 
the LPT and the MIS group (p value 0.83). Conversely, the 
number of pelvic lymph nodes removed was lower in the 
MIS group (median = 12, range 2–32) compared to the LPT 
one (median = 21, range 2–59) compared (p value 0.016).
Aortic lymph node status assessment was carried out in 
only 13 patients, due to suspicious lymph nodes at surgery 
(LPT 8, MIS 5). In the whole series, the median number of 
aortic lymph nodes removed was six (range 3–27) and did 
not differ between the two groups. Omentectomy was carried 
out in only seven patients (7.4%).
Pathologically assessed stage was: stage IA (N = 43), 
IB (N = 32), II (N = 20); stage II was more frequent in the 
MIS group compared to the LPT group, but the p value was 
not significant (p value = 0.51). All pelvic and aortic lymph 
nodes were histologically negative.
The tumor diameter was demonstrated to be larger in 
the LPT patients compared to the MIS group (median size 
7 cm, range 1–20 versus median size 5 cm, range 2–12.5, p 
value < 0.0001). The rate of positive lymphovascular space 
invasion (LVSI) was shown in 41.5% of all patients and did 
not differ between the two groups.
Adjuvant treatment
As shown in Table 1, in the whole series, 21 patients were 
triaged to surveillance due to very old age, and/or unsatisfac-
tory performance status (N = 19), or refusal (N = 2), while 73 
patients were administered adjuvant treatment; there was no 
difference in the distribution of adjuvant treatment between 
the two groups. Of patients undergoing adjuvant treatment, 
15 (20.3%) were administered radiotherapy, 29 (39.2%) were 
treated by only chemotherapy, and 30 (40.5%) were treated 
by chemotherapy followed by radiotherapy. There was no 
difference in the time interval from completion of surgery 
and start of adjuvant treatment between the two groups; the 
median time from surgery to the start of the adjuvant therapy 
was 6 weeks in both groups (data not shown).
Surgical details and intraoperative 
and postoperative morbidity
Surgical details are shown in Table 2: the operative time 
(OT) was lower in the MIS group versus the LPT group 
(median = 130 min, range 50–400 versus mediaN = 180 min, 
range 60–300) (p value = 0.021); the median estimated blood 
loss (EBL) was 50 cc (range 10–600) in the MIS group com-
pared to the median of 100 cc (range 100–2500) in the LPT 
group (p value < 0.0001) (Table 3).
As far as the hospital stay is concerned, the number of 
days was shorter in the MIS patients (median = 3, range 
2–10) versus the LPT group (median = 6.5, range 2–21) (p 
value < 0.0001). Only 1 intra-operative complication was 
documented: it occurred in the LPT group, and consisted 
in the lesion of the right obturator vein which was promptly 
repaired, though resulting in 2500 cc EBL. Overall, there 
were (15.0%) post-operative complications; they were more 
frequent in the LPT group (N = 7, 15.9%) versus the MIS 
group (N = 1, 2.0%) (p value = 0.023) (Table 2). In particu-
lar, in the LPT group there were five surgical complica-
tions (grade 2 wound dehiscence, grade lymphocele, grade 
3 hemoperitoneum, grade 5 duodenal perforation leading 
to death, and grade 5 abdominal abscess with death); there 
were also three medical complications including grade 2 
atrial fibrillation, and grade 2 lung failure in the LPT group, 
and only one grade 2 lower limbs neuropathy in the MIS 
group.
Clinical outcome
As for April 2020, follow-up was available in 91 patients 
due to the loss of data for 4 patients; overall, the median 
follow-up was 18  months (range 1–212), but patients 
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managed by MIS were operated in more recent years 
compared to the LPT patients (i.e. the percentage of MIS 
patients operated since 2010 was 93.7% versus 55.0% in 
the LPT group).
Overall, the number of recurrences was 34 (37.4%). Of 
these, 16/43 (37.2%) were documented in the LPT group, 
and 18/48 (37.5%) were in the MIS group. Overall, the 
most frequent site of recurrence was the central pelvic area 
Table 1  Patient characteristics
a calculated by the χ2 test or the Fisher’s exact test for proportions, and the Wilcoxon rank sum test for 
continuous data; baccording to the Querleu-Morrow  classification21; ccalculated based on no lymph node 
assessment versus lymph node assessment
LPT: laparotomic surgery, MIS: Minimally invasive surgery; BMI: Body Mass Index
N LPT
N. (%)
MIS
N. (%)
p  valuea
All 95 44 51
Age, years
 Median (range) 67 (39–88) 66 (50–88) 68 (39–88) 0.51
BMI, kg/m2
 Median (range) 28 (19–47) 28 (19–45) 28 (22–47) 0.67
Patients with morbidity
 No 22 12 (27.3%) 10 (19.6%) 0.28
 Yes 73 32 (72.7%) 41 (80.4%)
Type of  hysterectomyb 0.042
 A 81 34 (77.3%) 47 (92.1%)
 B1 14 10 (22.7%) 4 (7.8%)
Pelvic lymph node assessment 0.83c
 No 39 19 (43.2%) 20 (39.2%)
 Sampling 9 4 (9.1%) 5 (9.8%)
 Lymphadenectomy 47 21 (47.7%) 26 (51.0%)
No. of pelvic lymph nodes removed 0.016
 Median (range) 16 (2–59) 21 (2–59) 12 (2–32)
Aortic lymph node assessment 0.37c
 No 82 36 (81.8%) 46 (90.2%)
 Sampling 10 7 (15.9%) 3 (5.9%)
 Lymphadenectomy 3 1 (2.3%) 2 (3.9%)
No. of aortic lymph nodes removed 0.33
 Median (range) 6 (3–27) 8.5 (5–27) 6 (5–16)
Omentectomy 0.044
 No 88 38 (86.4%) 50 ()
 Yes 7 6 (13.6%) 1 ()
Stage 0.51
 IA 43 21 (47.7%) 22 (43.1%)
 IB 32 16 (36.4%) 16 (31.4%)
 II 20 7 (15.9%) 13 (25.5%)
Tumor diameter, cm  < 0.0001
 Median (range) 5.7 (1–20) 7 (1–20) 5 (2–12.5)
LVSI 0.51
 No 56 28 (63.6%) 28 (54.9%)
 Yes 39 17 (36.4%) 22 (45.1%)
Adjuvant treatment 0.8
 No 21 9 (20.4%) 12 (27.3%)
 Yes 74 35 (79.5%) 39 (72.7%)
  Radiotherapy 15 6 9
  Chemotherapy 29 17 12
  Chemotherapy + radiotherapy 30 12 18
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(N = 13) followed by distant sites (N = 12), and lymph nodes 
(N = 8) (Table 3).
As shown in Fig.  1a, there was no difference in the 
disease-free survival (DFS) between the two groups; the 
2-years DFS rate was 57% in the LPT group versus 62% in 
the MIS group (p value 0.628). Death of disease was regis-
tered in 31 patients (34.1%); the 3-years OS rate was 59% in 
the LPT group versus 63% in MIS groups (p value = 0.835) 
(Fig. 1b).
Univariate analysis of variables conditioning DFS in the 
whole series showed that only stage II was associated with 
Table 2  Surgical details, peri-
operative and post-operative 
complications
a calculated by the Wilcoxon rank sum test for continuous data; bcalculated by the Fisher’s exact test
All (N = 95) LPT (N = 44) MIS (N = 52) p  valuea
Operative time, min 0.021
 Median (range) 150 (50–400) 180 (60–300) 130 (50–400)
Estimated blood loss, cc  < 0.0001
 Median (range) 100 (10–2500) 200 (100–2500) 50 (10–600)
Length of hospitalization, days  < 0.0001
 Median (range) 4 (2–21) 6.5 (2–21) 3 (2–10)
Patients with intra-operative complications 1 1 -
 Right obturator vein lesion 1 1 -
Patients with post-operative complications 8 7 1 0.023b
 Grade II
  Atrial fibrillation 1 1 -
  Lung failure and delirium 1 1 -
  Lower limb neuropathy 1 – 1
  Wound dehiscence 1 1 -
 Grade III
  Pelvic lymphocele requiring drainage 1 1 –
  Hemoperitoneum 1 1 –
 Grade V
  Death (duodenal perforation) 1 1 –
  Death (abdominal abscess) 1 1 –
Table 3  Pattern of recurrences
All patients
N = 91
LPT
N = 43 (%)
MIS
N = 48 (%)
p value
Recurrence
 No 53 () 27 (62.8%) 30 (62.5%) 0.76
 Yes 34 () 16 (37.2%) 18 (37.5%)
  Central pelvic 11 6 7
  Lymph node 8 4 4
  Distant disease 9 5 7
  Unknown 1 1 –
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Fig. 1  Kaplan–Meier curves relative to DFS (a), and OS (b) according to the surgical approach
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statistically significant worse prognosis (p value 0.0002) 
(Table 4); in the multivariate analysis, stage II and tumor 
size were shown to play an independent, unfavorable role 
(Table 4). Univariate analysis of variables conditioning OS 
in the whole series showed that only stage II was associated 
with statistically significant worse prognosis; in the multi-
variate analysis, stage II and tumor size were associated with 
unfavorable clinical outcome (data not shown).
Discussion
UCSs are aggressive tumors, and are included in the “high-
risk” group according to the ESMO-ESGO-ESTRO clas-
sification (Colombo et al. 2016); however, the clinical out-
come of UCSs is even worse than clear cell, and serous EC 
(Koskas et al. 2016; Fader et al. 2016), thus emphasizing 
the need to better define the role of MIS focusing on this 
specific clinical setting. The current NCCN guidelines rela-
tive to all “high risk” EC suggest that MIS should be the 
preferred approach when technically feasible, based on a few 
retrospective studies (Fader et al. 2012; Koskas et al. 2016; 
Monterossi et al. 2017; Salehi et al. 2017), and on the sub-
analysis of the prospective phase III LAP2 trial (Fader et al. 
2016). Also, the LACE trial shows as in the endometrial 
cancer stage I MIS improves the quality of life after sur-
gery, decreases risk of major surgical adverse events without 
impacting on disease-free survival at 4.5 years and on over-
all survival (Janda et al. 2010, 2017; Obermair et al. 2012).
However, the studies specifically focused on the role of 
MIS versus LPT only in UCSs are few, and also include 
advanced stage of disease (Fader et al. 2012; Koskas et al. 
2016; Salehi et al. 2017).
To our knowledge, our study represents the largest, retro-
spective series comparing the role of MIS versus LPT only 
in pathologically assessed stage I–II disease UCSs: there 
was no difference in terms of oncologic outcome between 
the two approaches, in face of a more favourable peri-oper-
ative and post-operative profile in the MIS group.
As far as the surgical procedures are concerned, the rate 
of type B1 hysterectomy was lower in the MIS patients, a 
finding which could be ascribed to the smaller tumor diam-
eter in the MIS group, as also suggested in previous studies 
(Koskas et al. 2016). Assessment of pelvic lymph node sta-
tus was carried out in about 60% of overall patients; in this 
context, we have to acknowledge that > 75% of our patients 
had comorbidities, and around one-third were obese, and 
this could have led to spare patients pelvic lymphadenec-
tomy to limit the operative time, and also reduce surgical 
morbidity since the high aggressiveness of this histologi-
cal subtype strongly increases the probability that patients 
would require adjuvant treatment. Finally, it has been rec-
ognized that in the real-world practice, only 35–57% of 
patients in some gynecologic oncology centres in USA 
were triaged to lymphadenectomy, as summarized in the 
Vorgias review (Vorgias and Fotiou 2010); as a matter 
of fact, even considering the large series from the SEER 
database (N = 1885 patients), and the Netherland Cancer 
registry (N = 1140 patients), the “lymphadenectomy issue” 
still remains controversial (Nemani et al. 2008; Versluis 
et al. 2018); indeed, the SEER study concluded that lym-
phadenectomy is associated with improved overall survival 
with no benefit associated to adjuvant radiotherapy (Nem-
ani et al. 2008), while the Dutch study demonstrates that 
(1) lymphadenectomy is related to improved survival only 
if > 10 lymph nodes are removed, and (2) adjuvant therapy 
improves survival when lymphadenectomy is omitted, or 
when lymph nodes are positive (Versluis et  al. 2018). 
Probably, these conflicting findings could be related to the 
fact that the two studies included also stage III (Nemani 
Table 4  Univariate and multivariate analysis of features conditioning PFS in the whole series (N = 80)
a calculated by Cox regression
LVSI lymphovascular space involvement, MIS minimally invasive surgery, LPT laparotomy
Variable Univariate Multivariate
β Hazard ratio (CI 95%) p valuea β Hazard ratio (CI 5%) p valuea
Age
 (≤ 67 years vs. > 67 years) 0.349 1.418 (0.719–2.796) 0.313 0.242 0.875 (0.324–1.902) 0.592
Stage
 (I vs. II) 1.100 3.003 (1.495–2.796) 0.002 1.551 4.715 (1.837–12.099) 0.001
Size of tumor
 (≤ 60 mm vs. > 60 mm) 0.567 1.762 (0.847–3.666) 0.129 1.342 3.826 (1.457–10.047) 0.006
LVSI
 (No vs. yes) − 0.116 0.890 (0.437–1.812) 0.748 − 0.817 0.442 (0.186–1.046) 0.079
Surgical approach
 (LPT vs. MIS) 0.166 1.180 (0.599–2.326) 0.632 0.810 2.240 (0.850–5.947) 0.102
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et al. 2008; Versluis et al. 2018), and even stage IV disease 
(Versluis et al. 2018). Indeed, in the large series includ-
ing 5614 stage I UCS patients, lymphadenectomy ≥ 15–20 
lymph nodes removed was associated with better survival 
(Seagle et al. 2017).
Some recent lines of evidence have been reported relative 
to the possibility to adopt the sentinel lymph node mapping 
(SLN) also in UCS patients (Schiavone et al. 2016), as also 
recommended for low-risk EC (Leitao et al. 2013; Holloway 
et al. 2017); Indeed, Schiavone et al. (2016) reported simi-
lar progression-free survival in UCSC patients (stage I–IV) 
undergoing SLN and adjuvant therapy compared to system-
atic lymphadenectomy. The confirmation of these findings in 
a larger series could lead to guarantee the staging of disease 
while sparing potential morbidities.
As expected, MIS provided reduced median operative 
time, and blood loss, and also guaranteed a faster return 
home, as largely reported (Walker et al. 2009; Fader et al. 
2016).
There was only one intraoperative complication in the 
LPT group; on the other hand, seven (15.9%) postoperative 
complications were registered in the LPT group versus only 
one postoperative complications in the MIS one (p value 
0.023): of these, five were surgical morbidities including 
three patients with grade 3 morbidities, and two patients 
experiencing grade 5 morbidities leading to death.
The short hospitalization interval, and the low postop-
erative morbidity profile may fasten the administration of 
adjuvant treatment, which was carried out in approximately 
75% of our patients; the distribution of treatments was simi-
lar between the two groups, as well as the time interval from 
surgery to the start of the adjuvant therapy. However, due 
to the retrospective design of our study, some data about 
adjuvant therapy were missed, thus representing a bias of the 
study. In particular, it has been impossible to find accurate 
radiotherapy data.
As far as the oncologic outcome is concerned, we have to 
acknowledge that the patients managed by MIS were oper-
ated in a more recent time frame, thus leading to shorter 
follow duration; overall, relapse of disease occurred in was 
37.4%, a figure which appears higher compared to the lit-
erature; however, the percentage of stage II was higher than 
expected.
In our series, multivariate analysis led to define stage II of 
disease, and tumor size as independent, unfavourable prog-
nostic parameters for DFS and OS; this could be ascribed to 
the fact that this study has focused only on pathologically 
assessed stage I–II patients, in which the lymph node status 
and extrauterine disease was not contemplated. Despite the 
bias potentially associated with the retrospective design and 
the sample size, we demonstrated that the MIS approach was 
shown not to be detrimental to the clinical outcome.
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